IL6 and gastric cancer: Additionally, the deployment of neutralizing antibodies to deplete IL-6 or the application of the specific inhibitor AG490 to impede the JAK/STAT3 pathway significantly mitigates these CAF-induced phenotypic traits in gastric cancer cells and curtails their metastatic propensity [118].